The nation of Zimbabwe has turned down a major American health deal worth $367m (£272m) over five years over Washington's request for sensitive biological samples.
This rejection became public after a official document from December was leaked, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "skewed".
An official spokesman later clarified that the US was requesting biological samples for scientific study and profit while refused to guarantee the resulting advantages from future treatments.
"We are forced to start the difficult and regrettable process of ending our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had donated more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged further talks to find a agreement acceptable to all parties so the country's critical HIV treatment initiative can continue.
Wider Context
This development comes after a similar case in Kenya, where a court blocked a similar health funding agreement following legal challenges were raised about the safety of Kenyans' health data.
Since resuming the presidency last year, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump claimed its expenditure was "inefficient" and his government was seeking direct bilateral agreements to enhance openness and responsibility.
According to reports, 16 nations in Africa have to date agreed to these new health pacts, representing over $18.3bn in committed funds.
Specifics of the Rejected Agreement
This assistance for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation might have yielded extraordinary advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently receiving HIV treatment via American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"Our nation was requested to provide its genetic material and health information over an extended period, without any equivalent assurance of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," Mangwana explained.
"Put simply, our nation would supply the raw materials for scientific discovery with no certainty that the end products would be available to our people if a new health crisis emerge."
Sovereignty and International Frameworks
He also pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were disrupting structures already established through the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework designed to deal with future pandemics.
"This framework is intended to ensure that when a nation contributes its samples, the benefits – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the resources to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We welcome continued dialogue with our US partners on how subsequent co-operation could be structured in a manner that respects the independence and dignity of each country."
Health Experts Response
Medical experts said it understood the government's concerns, but suggested that talks need to persist since much of the country's HIV programmes depended on international support.
"If technical issues exist, including those relating to data governance or implementation frameworks, these can frequently be addressed through detailed discussion and negotiated safeguards," it added.
The situation emphasises the ongoing debate between receiving crucial foreign assistance and safeguarding national sovereignty in an ever more data-driven world.